Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin Irritation Trial of LEO 90100 Foam in Healthy Japanese Subjects
NCT03442244Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Jan 2018
- Primary completion
- Feb 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of calcipotriol in Psoriasis vulgaris (PV) (2 arms), sponsored by LEO Pharma. Primary endpoints: Skin irritation at Day 4 and Photo irritation at Day 4. Started Jan 2018; status: completed.
02
Drugs
calcipotriol
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT03442244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03442244.